Analysts and Technical News on Ligand Pharmaceuticals Inc (NASDAQ:LGND)

Ligand Pharmaceuticals Inc (NASDAQ:LGND) (Trend Analysis) shares were traded with no significant volume change. The stock closed last trading session at $105.6, up by 0.79%, with a volume of 535,893 shares against an average amount for the last three months of 400,335.

Stock Performance: Click here for a free comprehensive Trend Analysis Report

Ligand Pharmaceuticals Inc (NASDAQ:LGND) stock is currently trading 24.46% below its 52-week-high, 28.69% above its 52-week-low. The 1-year stock price history is in the range of $82.06 – $139.79. Ligand Pharmaceuticals Inc (LGND) has a price to earnings ratio of 241.1 versus Healthcare sector average of 40.79. LGND stock price has underperformed the Nasdaq by 8.6%. The Biotechnology company is currently valued at $2.21 billion, and its share price closed the last trading session at $105.6. The stock has a 50-day moving average of $98.9 and a 200-day moving average of $113.62.

Ligand Pharmaceuticals Inc (LGND) current short interest stands at 4.54 million shares. It has increased by 6% from the same period of last month. Around 24% of the company’s shares, which are float, are short sold. With a 10-days average volume of 0.47 million shares, the number of days required to cover the short positions stand at 9.8 days.

Ligand Pharmaceuticals Inc (LGND) declared last quarter earnings on November 03. The Biotechnology company announced last quarter earnings per share of $0.03 against a consensus Street estimate of $0.09, missing estimate by $0.06. The company posted a revenue of $21.6 million compared to an estimation of $23.5 million.

Is this a Trading Opportunity? Click here for a free Trend Analysis Report

There are currently six analysts that cover Ligand Pharmaceuticals Inc stock. Of those six, five have a Buy rating, one has a Hold rating. On a consensus basis this yields to a Buy rating. The consensus target price stands at $138.17.

A recent analyst activity consisted of H.C. Wainwright reiterating their Buy stance on October 5. H.C. Wainwright increased their price target on LGND from $146 to $160. This corresponds to a 51.52% upside from the last closing price. On the date of report, the stock closed at $101.28.

Roth Capital reiterated their Buy stance on September 27, and decreased their price target from $151 to $150. This corresponds to a 42.05% upside from the last closing price. On the date of report, the stock closed at $99.64.

Ligand Pharmaceuticals Inc (LGND) has a debt to equity ratio of 758% compared to Healthcare sector average of 70%. The company has a current ratio of 0.62. This ratio should be higher than one (ideally two) and is an indicator to show if the company is able to finance its short term obligations. Indeed, it should have higher short term assets to dispose in order to cover for its short term liabilities.

Company snapshot

Ligand Pharmaceuticals Incorporated develops drugs which regulate hormone activated intracellular receptors. These receptors play a role in regulating the genetic processes affecting diseases such as gynecological disorders, certain cancers, as well as cardiovascular, inflammatory, and skin diseases.

Analysts and Technical News on Ligand Pharmaceuticals Inc (NASDAQ:LGND) was last modified: November 11th, 2016 by Pat Mayfield